Table 5. Most recent series of early, well-differentiated, endometrioid endometrial cancer conservatively treated by progestin alone.
| Study | No. | Progestin treatment (mg/day) | Oncologic outcome at 6 mo | Relapse | DFI (mo) | Pregnancy (no. of patients) | Live births | Follow-up (mo) | Current status |
|---|---|---|---|---|---|---|---|---|---|
| Cade et al. (2010) [32] | 16 | MPA (60–400), LNG-IUD, or both | 7 CR, 9 PD | 2 | NR | 3 | 4 | 3–134 | NED |
| Koskas et al. (2012) [33] | 8 | MA (160), MPA (10), Ly (15), or NA (5) | 5 CR, 1 P, 2 PD | 2 | 12–34 | 2 | 3 | 17–86 | NED |
| Kim et al. (2013) [34] | 16 | Combined MPA (500) and LNG-IUD | 9 CR, 7 PD | 2 | 6–7 | 3 | 2 | 16–50 | NED |
| Park et al. (2013) [29] | 148 | MPA (30–1,500) or MA (40–240) | 115 CR, 33 PD | 35 | 4–61 | 44 | NR | 14–194 | NED |
| Kudesia et al. (2014) [35] | 10 | MA (160–240), LNG-IUD, or both | 7 CR, 3 PD | NR | NR | NR | 2 | 3–74 | NR |
| Ohyagi-Hara et al. (2015) [36] | 16 | MPA (400–600) | 11 CR, 1 P, 4 PD | 9 | NR | 1 | 2 | 4–154 | NR |
CR, complete regression; DFI, disease-free interval; LNG-IUD, levonorgestrel intrauterine device; Ly, lynestrenol; MA, megestrol acetate; MPA, medroxyprogesterone acetate; NA, nomegestrol acetate; NED, no evidence of disease; NR, not reported; P, progression; PD, persistent disease.